Insulet Corporation (PODD)
NMS · Medical Devices
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Peers in Medical Devices
All in industry →Abbott Laboratories
Stryker Corporation
Medtronic plc
Boston Scientific Corporation
Edwards Lifesciences Corporation
GE HealthCare Technologies Inc.
Koninklijke Philips N.V.
DexCom, Inc.
STERIS plc
Zimmer Biomet Holdings, Inc.
Recent press releases
April 2026
INSULET CORP — DEF 14A Filing
# 🔥 What This Document Is This is Insulet's **definitive proxy statement (DEF 14A)**. Think of it as the official invitation and information packet for the company's annual shareholder meeting. It's required by the SEC and tells you everything you need to know to vote your shares. 👉 **Why it mat
SEC filings
All filings →Insider trades
All insider trades →Insulet Corporation has no reported insider trades in the last 90 days.